HRS-7535
Asset
Oral GLP-1 receptor agonist
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Insulin/IGF-1 signalling
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Type 2 diabetes
Phase 3, Completed, NCT06589765, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.